In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 3, 2014, Pages 1102-1107

  Dunn, Gavin P ^a,b,c   Cheung, Hiu Wing ^b,c   Agarwalla, Pankaj K ^a,b,d   Thomas, Sapana ^c   Zektser, Yulia ^c   Karst, Alison M ^b   Boehm, Jesse S ^c   Weir, Barbara A ^c   Berlin, Aaron M ^c   Zou, Lihua ^c   Getz, Gad ^c   Liu, Joyce F ^b,d   Hirsch, Michelle ^d   Vazquez, Francisca ^c   Root, David E ^c   Beroukhim, Rameen ^b,c,d   Drapkin, Ronny ^b,d   Hahn, William C ^b,c,d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Functional genomics; Open reading frame; ORF

Indexed keywords

ADAPTOR PROTEIN; BINDING PROTEIN; GAB 2 PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CONTROLLED STUDY; ENZYME ACTIVATION; EPITHELIUM CELL; FEMALE; GENE AMPLIFICATION; GENE IDENTIFICATION; HUMAN; HUMAN CELL; IN VIVO STUDY; ONCOGENE; OVARY CANCER; PRIORITY JOURNAL; UTERINE TUBE;

FUNCTIONAL GENOMICS; OPEN READING FRAME; ORF;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMICS; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OPEN READING FRAMES; OVARIAN NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; SIGNAL TRANSDUCTION;

EID: 84892939483     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1311909111     Document Type: Article

References (37)

1. Soslow RA (2008) Histologic subtypes of ovarian carcinoma: An overview. Int J Gynecol Pathol 27(2):161-174.
2. Tothill RW, et al. Australian Ovarian Cancer Study Group (2008) Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 14(16):5198-5208.
3. Cancer Genome Atlas Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474(7353):609-615.
4. Cheung HW, et al. (2011) Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci USA 108(30):12372-12377.
5. Ren Y, et al. (2012) Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4. Sci Transl Med 4(147):ra112.
6. Zender L, et al. (2008) An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell 135(5):852-864.
7. Rui L, et al. (2010) Cooperative epigenetic modulation by cancer amplicon genes. Cancer Cell 18(6):590-605.
8. Boehm JS, et al. (2007) Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 129(6):1065-1079.
9. Shrestha Y, et al. (2012) PAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signaling. Oncogene 31(29):3397-3408.
10. Liang H, et al. (2012) Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res 22(11):2120-2129.
11. Sawey ET, et al. (2011) Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. Cancer Cell 19(3):347-358.
12. Yang X, et al. (2011) A public genome-scale lentiviral expression library of human ORFs. Nat Methods 8(8):659-661.
13. Hahn WC, et al. (2002) Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol Cell Biol 22(7):2111-2123.
14. Counter CM, et al. (1998) Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization. Proc Natl Acad Sci USA 95(25):14723-14728.
15. Hahn WC, Weinberg RA (2002) Rules for making human tumor cells. N Engl J Med 347(20):1593-1603.
16. Bentires-Alj M, et al. (2006) A role for the scaffolding adapter GAB2 in breast cancer. Nat Med 12(1):114-121.
17. Ke Y, et al. (2007) Role of Gab2 in mammary tumorigenesis and metastasis. Oncogene 26(34):4951-4960.
18. Karst AM, Levanon K, Drapkin R (2011) Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. Proc Natl Acad Sci USA 108(18):7547-7552.
19. Brown LA, et al. (2008) Amplification of 11q13 in ovarian carcinoma. Genes Chromosomes Cancer 47(6):481-489.
20. Mermel CH, et al. (2011) GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol 12(4):R41.
21. The Broad Institute Portal Team (2012) TCGACopy Number Portal. Available at www.broadinstitute.org/tcga/home. Accessed November 20, 2012 (data freeze).
22. Bocanegra M, et al. (2010) Focal amplification and oncogene dependency of GAB2 in breast cancer. Oncogene 29(5):774-779.
23. Barretina J, et al. (2012) The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483(7391):603-607.
24. Horst B, et al. (2009) Gab2-mediated signaling promotes melanoma metastasis. Am J Pathol 174(4):1524-1533.
25. Bast RC, Jr., Mills GB (2012) Dissecting "PI3Kness": The complexity of personalized therapy for ovarian cancer. Cancer Discov 2(1):16-18.
26. Wang Y, Sheng Q, Spillman MA, Behbakht K, Gu H (2012) Gab2 regulates the migratory behaviors and E-cadherin expression via activation of the PI3K pathway in ovarian cancer cells. Oncogene 31(20):2512-2520.
27. Qiu L, et al. (2013) Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR. Cancer Res 73(8):2574-2586.
28. Hanrahan AJ, et al. (2012) Genomic complexity and AKT dependence in serous ovarian cancer. Cancer Discov 2(1):56-67.
29. O'Brien C, et al. (2010) Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res 16(14):3670-3683.
30. Shih IeM, et al. (2005) Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. Proc Natl Acad Sci USA 102(39):14004-14009.
31. Sattler M, et al. (2002) Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell 1(5):479-492.
32. Davis SJ, et al. (2013) Functional analysis of genes in regions commonly amplified in high-grade serous and endometrioid ovarian cancer. Clin Cancer Res 19(6):1411-1421.
33. Bast RC, Jr., Hennessy B, Mills GB (2009) The biology of ovarian cancer: New opportunities for translation. Nat Rev Cancer 9(6):415-428.
34. Shi J, et al. (2012) Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer. BMC Cancer 12:50.
35. Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61-70.
36. Janku F, et al. (2012) PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol 30(8):777-782.
37. Cheung HW, et al. (2011) Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. Cancer Discov 1(7):608-625.